Abstracts tagged "Pharmacoepidemiology"

Abstract Number: 0031 • ACR Convergence 2021
A New Pharmacostatistical Model to Assess MTX-adherence in RA Patients
Marion Geoffroy¹, Claire Gozalo², Loic Pauvele², Elise Abboud², Zoubir Djerada³ and Jean hugues Salmon⁴, ¹CHU Reims, France, REIMS, France, ²CHU Reims, Reims, France, ³CHU Riems, Reims, France, ⁴Rheumatology, CHU Maison blanche, Reims, Reims, France
Background/Purpose: Methotrexate (MTX) is the first-line therapy for rheumatoid arthritis (RA). While therapeutic adherence is essential to the successful management of the patient, an estimated…
Abstract Number: 0101 • ACR Convergence 2021
Herpes Zoster Recombinant Zoster Vaccination Among Adults Age ≥50 Years with Immune Mediated Inflammatory Diseases in the United States
Jessica Leung¹, Tara Anderson¹, Kathleen Dooling¹, Fenglong Xie² and Jeffrey Curtis³, ¹Centers for Disease Control, Atlanta, GA, ²University of Alabama at Birmingham, Birmingham, AL, ³Division of Clinical Immunology and Rheumatology, Department of Medicine, Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Persons with immune mediated Inflammatory diseases (IMIDs) are at increased risk of developing herpes zoster (HZ) and postherpetic neuralgia. In 2018, CDC recommended a…
Abstract Number: 0573 • ACR Convergence 2021
Biosimilar to Biosimilar Infliximab Switching in Real-world Patients with Inflammatory Arthritis Followed in the Danish DANBIO Registry: Switch from Originator Infliximab to CT-P13 and Then to GP1111
Hafsah Nabi¹, Bente Glintborg², Anne Gitte Loft³, Oliver Hendricks⁴, Jens Kristian Pedersen⁵, Søren Andreas Just⁶, Rabiah Ahmed⁷, Kamilla Danebod⁷, Heidi Munk⁸, Ada Colic⁹, Asta Linauskas¹⁰, Dorte Vendelbo Jensen¹¹, Johnny Raun¹², Jolanta Grydehøj¹³, Louise Brot Christensen¹⁴, Natalia Manilo¹⁵, Niels Lomborg¹⁶, Salome Kristensen¹⁷, Frank Mehnert¹⁸, Niels Steen Krogh¹⁹ and Merete Hetland²⁰, ¹DANBIO and Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre of Head and Orthopedics, Rigshospitalet, Copenhagen, Denmark, ²COPECARE, Centre for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Denmark, Glostrup, Denmark, ³Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, ⁴Danish Hospital for Rheumatic Diseases, University Hospital of Southern Denmark, Snderborg, Denmark, ⁵Section of Rheumatology, Department of Medicine, Svendborg Hospital – Odense University Hospital, Svendborg, Denmark, ⁶Section of Rheumatology, Dept. of Medicine, Svendborg Hospital, Svendborg, Denmark, ⁷Department of Rheumatology, Center for Rheumatology and Spine Diseases, Centre of Head and Orthopedics, Rigshospitalet, Copenhagen University Hospital, Glostrup, Copenhagen, Denmark, ⁸Department of Rheumatology, Odense University Hospital, Odense, Denmark, ⁹Department of Rheumatology, Zealand University Hospital, Køge, Denmark, ¹⁰Department of Rheumatology, North Denmark Regional Hospital, Hjoerring, Denmark, ¹¹Department of Internal Medicine, Rønne Hospital, Rønne, Denmark, ¹²Department of Rheumatology, Sygehus Lillebælt, Fredericia, Denmark, ¹³Department of Rheumatology, Holstebro Hospital, Holstebro, Denmark, ¹⁴Department of Rheumatology, Gentofte and Herlev Hospital, Copenhagen University Hospital, Gentofte, Denmark, ¹⁵Department of Rheumatology, Frederiksberg Hospital, Frederiksberg, Denmark, ¹⁶Department of Rheumatology, Vejle Hospital Lillebælt, Vejle, Odense C, Denmark, ¹⁷Department of Rheumatology, Aalborg University Hospital, Aalborg, Denmark, ¹⁸Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark, ¹⁹ZiteLab ApS, Copenhagen, Denmark, Frederiksberg, Denmark, ²⁰DANBIO and COPECARE, Centre for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Denmark
Background/Purpose: In routine care, biosimilar to biosimilar infliximab switching may occur to save costs (=non-medical switching). Previous studies have investigated the efficacy and safety of…
Abstract Number: 0534 • ACR Convergence 2020
National Variation and Factors Associated with Long-term Opioid Use for Non-cancer Pain in the First Year of Use
Meghna Jani¹, Belay Yimer¹, Therese Sheppard¹, Mark Lunt¹ and William Dixon¹, ¹Centre for Epidemiology Versus Arthritis, University of Manchester, Manchester, United Kingdom
Background/Purpose: Physician prescribing behaviour has been described as a key driver of rising opioid prescriptions and long-term opioid use. However, the effect of prescribers requires…
Abstract Number: 0550 • ACR Convergence 2020
Mapping Multimorbidity Using Drug Concept Unique Identifiers (RxCUIs) via the Rx-Risk Comorbidity Index
Jared Vanderbleek¹, Justin Owensby¹, Alex Mccannaly¹, Lang Chen¹, Bryant England², Jeffrey R Curtis³ and Huifeng Yun³, ¹University of Alabama at Birmingham, Birmingham, AL, ²University of Nebraska Medical Center, Omaha, NE, ³Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Identifying and accurately classifying comorbid conditions in large, real-world data sources is crucial for cohort establishment and confounder adjustment. However, the ability to conduct…
Abstract Number: 0594 • ACR Convergence 2020
Mechanical and Temperature Stress During Biologic Shipments to Rheumatology Patients
Sarah Dill¹, Elizabeth Cheng², Kyle Brees², John Carpenter³ and Liron Caplan², ¹University of Colorado, Denver, CO, ²Rocky Mountain Regional Veterans Affairs Medical Center, Aurora, CO, ³University of Colorado Skaggs School of Pharmacy, Aurora, CO
Background/Purpose: Biologic medications are expensive, and unfortunately their immunogenicity contributes to loss of efficacy over time. Protein particles may form as a result of medication…
Abstract Number: 1122 • ACR Convergence 2020
Osteoarthritis in a Large Integrated Health System Population: 18-Year Retrospective Review
Jove Graham¹, Tonia Novosat¹, Haiyan Sun¹, Brian Piper², Joseph Boscarino¹, Melissa Kern¹, Vanessa Duboski³, Eric Wright³, Patricia Schepman⁴, Rebecca Robinson⁵, Edward Casey⁶, Craig Beck⁷ and Jerry Hall⁸, ¹Geisinger, Danville, ²Geisinger, Scranton, ³Geisinger, Forty Fort, ⁴Pfizer, New York City, NY, ⁵Eli Lilly and Company, Indianapolis, ⁶Pfizer, New York, ⁷Pfizer, London, ⁸Eli Lilly and Company, Indianapolis, IN
Background/Purpose: Osteoarthritis (OA) is a mechanically and immunologically mediated common disease with a complex pathogenesis. Despite epidemiologic studies proving increasing age, obesity and female gender…
Abstract Number: 1481 • ACR Convergence 2020
A Systematic Review to Quantify the Extent of Pharmaceutical Company Involvement in Rheumatology Consensus-Based Recommendations
Dominique Feterman Jimenez¹, Garret Duron², Ali Duarte-Garcia³, Paul Sufka⁴, Samuel Whittle⁵, Philip Robinson⁶, Larry Prokop³ and Michael Putman⁷, ¹UConn Health Center, Farmington, CT, ²HCA Memorial Health University Medical Center, Savannah, GA, ³Mayo Clinic, Rochester, MN, ⁴Healthpartners, St Paul, ⁵Rheumatology Unit, The Queen Elizabeth Hospital, Springfield, South Australia, Australia, ⁶University of Queensland, Herston, Queensland, Australia, ⁷Northwestern University, Chicago, IL
Background/Purpose: Consensus-based recommendations guide standards of care for clinical practice. Pharmaceutical-industry involvement in producing such recommendations may undermine their objectivity. We performed a systematic review…
Abstract Number: 1570 • ACR Convergence 2020
Immune Checkpoint Inhibitor Treatment in Cancer: Immunomodulator Use and Evaluation by Rheumatology
Amy Cunningham-Bussel¹, Jiaqi Wang¹, Lauren C. Prisco², Lily Martin², Lydia Gedmintas¹, Lindsey Macfarlane¹, Nancy Shadick¹, Mark Awad³, Osama Rahma³, Nicole LeBoeuf³, Ellen Gravallese¹ and Jeffrey Sparks¹, ¹Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Boston, ³Dana-Farber Cancer Institute, Boston, MA
Background/Purpose: Immune checkpoint inhibitors (ICI) are used to treat an expanding number of cancers. Many cancer patients treated with ICI develop immune-related adverse events (irAE)…
Abstract Number: 1637 • ACR Convergence 2020
Comparison of Nation-wide Epidemical Study on 2009 and That on 2019 Revealed That Improvement of Disease Severity and Mortality Rate May Come from Progress of Proficient Management in Patients with Relapsing Polychondritis in Japan
Jun Shimizu¹, Yoshihisa Yamano¹, Kimito Kawahata² and Noboru Suzuki¹, ¹St. Marianna University School of Medicine, Kawasaki, Japan, ²Division of Rheumatology and Allergology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan
Background/Purpose: We conducted a retrospective survey study in 2009 and collected clinical data of 239 patients with relapsing polychondritis (RP). Using the survey data, we…
Abstract Number: 1993 • ACR Convergence 2020
Cardiovascular Risk in Rheumatoid Arthritis Patients Treated with Methotrexate versus Hydroxychloroquine
Mengdong He¹, Ajinkya Pawar¹, Rishi Desai¹, Robert Glynn¹, Hemin Lee¹, Michael Weinblatt¹, Daniel H Solomon¹ and Seoyoung Kim¹, ¹Brigham and Women's Hospital, Boston, MA
Background/Purpose: Rheumatoid arthritis (RA) is a known risk factor for cardiovascular (CV) events. While most RA patients use conventional disease-modifying antirheumatic drugs (DMARDs) such as…
Abstract Number: 2000 • ACR Convergence 2020
Risk of Venous Thromboembolism in Rheumatoid Arthritis Patients Treated with Methotrexate versus Hydroxychloroquine
Mengdong He¹, Ajinkya Pawar¹, Rishi Desai¹, Robert Glynn¹, Hemin Lee¹, Michael Weinblatt¹, Daniel H Solomon¹ and Seoyoung Kim¹, ¹Brigham and Women's Hospital, Boston, MA
Background/Purpose: Prior studies suggest an increased risk of venous thromboembolism (VTE) among patients with rheumatoid arthritis (RA). However, little is known about the comparative risk…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].